VYNE Therapeutics filed an exhibit containing a Yarrow Bioscience company overview presentation dated May 2026, indicating preparation for a proposed reverse merger transaction with concurrent financing. The filing suggests potential corporate restructuring activity that could materially impact VYNE's capital structure and business operations.